Suivre
Abonner IsoTis OrthoBiologics

IsoTis OrthoBiologics

Filtre
  • 29.10.2007 – 22:59

    Majority of IsoTis Stockholders Vote for Integra Acquisition

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders re-convened earlier today, IsoTis stockholders have approved the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The acquisition is ...

  • 27.10.2007 – 01:05

    IsoTis Adjourns Special Meeting to October 29, 2007

    Irvine, California (ots/PRNewswire) - - Less Than 40,000 Additional "FOR" Votes Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned its special meeting of stockholders again, to Monday, October 29, 2007, to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an ...

  • 26.10.2007 – 19:29

    IsoTis Reports Status of Merger Vote

    Irvine, California (ots/PRNewswire) - - Less than 100,000 Additional "FOR" Votes Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today reported that less than 100,000 votes "FOR" are needed to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, ...

  • 24.10.2007 – 16:24

    IsoTis Adjourns Special Meeting to October 26, 2007

    Irvine, California (ots/PRNewswire) - - Less Than 350,000 Additional Votes "FOR" Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders again, to October 26, 2007, to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement ...

  • 16.10.2007 – 09:00

    IsoTis Reports Interim Results of Vote for Integra Merger

    Irvine, California (ots/PRNewswire) - - Conference Calls to Answer Questions About Stockholder Meeting October 23 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the interim tabulation results of the special stockholders meeting held on October 11, 2007 and adjourned to October 23, 2007. Prior to October 11, 2007, approximately 2,555,000 shares, 36 percent of the shares ...

  • 11.10.2007 – 23:13

    IsoTis Adjourns Special Meeting to October 23, 2007

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders it called to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The special meeting of stockholders was held at ...

  • 19.09.2007 – 14:10

    IsoTis - Integra Merger

    Irvine, California (ots/PRNewswire) - - Leading Proxy Advisor Recommends Shareholders Support Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that Institutional Shareholder Services, ISS, a leading proxy advisor, recommends shareholders support the merger of IsoTis and Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra"). For every M&A analysis, ISS reviews publicly available information and evaluates ...

  • 05.09.2007 – 22:27

    IsoTis Files Definitive Proxy Statement

    Irvine, California (ots/PRNewswire) - - Special Stockholders Meeting to Approve Merger With Integra on October 11, 2007 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the filing of a definitive proxy statement with the U.S. Securities and Exchange Commission ("SEC") in connection with the IsoTis-Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") combination. ...

  • 20.08.2007 – 14:31

    IsoTis Receives FDA Clearance for Accell Family of Products

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it received a letter dated August 15, 2007 from the US Food and Drug Administration ("FDA"), clearing the Accell Family of Products for marketing in the US as Class II medical devices. The Accell Family of Products includes Accell 100, Accell Connexus and Accell Total Bone Matrix, as well as ...

  • 03.08.2007 – 16:19

    IsoTis to Release Second Quarter 2007 Results on August 7

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDQ: ISOT), a leading orthobiologics company, will release its 2007 second quarter results before opening of trading on Tuesday, August 7, 2007. To discuss these results, the Company will conduct a conference call at 4:00 p.m. (Eastern Time) / 1:00 p.m. (Pacific Time)/ 10:00 p.m. (Central European Time). Dial in details will be provided in the Q2 2007 release on ...

  • 25.07.2007 – 14:09

    IsoTis SA to Delist From SWX, Euronext, and TSX on July 30, 2007

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company ("IsoTis"), today announced that it has concluded the squeeze-out merger of ISOTIS SA following an Extraordinary General Meeting of shareholders on July 23, 2007. As a result, ISOTIS SA has merged with and into IsoTis International SA, a wholly-owned subsidiary of IsoTis, and no longer exists as a separate legal entity. After ...

  • 18.06.2007 – 16:07

    IsoTis Expects Delisting From SWX, Euronext, and TSX in July 2007

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that it is at the final stage of concluding the Exchange Offer it launched for all of the outstanding shares of ISOTIS SA on December 15, 2006. After this last step of the Exchange Offer, ISOTIS SA will no longer be listed on SWX Swiss Exchange, Euronext Amsterdam and the Toronto Stock Exchange. On ...

  • 30.05.2007 – 15:22

    IsoTis Regulatory Review of Accell Products Back on Track

    Irvine, California (ots/PRNewswire) - - FDA Reinitiates 510(k) Review IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that it recently received a positive response from the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA), confirming that IsoTis' Accell family of demineralized ...

  • 30.05.2007 – 14:47

    IsoTis Closes on $20 Million Credit Facility With Merrill Lynch Capital & Silicon Valley Bank

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced it has secured a $20 Million credit facility with Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc., and Silicon Valley Bank. The three-year $20 million credit facility has two components: a $10 million term loan and a ...

  • 15.05.2007 – 14:21

    IsoTis Reports 2007 First Quarter Results

    Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), an orthobiologics company, today reported results for the first quarter ended March 31, 2007. Revenue Analysis Revenue was US$10.0 million for the first quarter of 2007, representing a 2% increase over revenue of US$9.8 million for the first quarter of 2006. IsoTis' chief distribution channels are its U.S. network of independent distributor ...

  • 09.05.2007 – 14:28

    IsoTis to Release First Quarter 2007 Results on May 15

    Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), a leading orthobiologics company, will release its first quarter 2007 results on May 15 at approximately 4:30 p.m. EST . To discuss these results, the Company will conduct a conference call at 5 p.m. EST / 2:00 p.m. PST/ 11:00 p.m. CET. US Dial In: 1-617-614-6206; UK Dial In +44-20-7365-8426; Continental Europe Dial In: +41-1-800-9569; password: ...

  • 03.05.2007 – 14:16

    IsoTis Receives US Patent Related to Reverse Phase Medium Technology

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that the United States Patent and Trademark Office has awarded US Patent No. 7,205,337, which relates to the company's Reverse Phase Medium (RPM) carrier technology. The patent covers the use of IsoTis' current RPM technology in combination with various demineralized bone matrix (DBM) formulations, such as ...

  • 25.04.2007 – 14:17

    IsoTis Completes Transfer of PolyActive IP Estate to OctoPlus

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced it has completed the transfer of the rights associated with its PolyActive technology to OctoPlus (Euronext: OCTO), a drug delivery and development company, in exchange for an up-front payment of approximately $1.7 million and future royalty payments on sales of pharmaceutical products based on the ...

  • 16.04.2007 – 14:15

    /C O R R E C T I O N -- Isotis Inc/

    Irvine, California (ots/PRNewswire) - In the news release, "IsoTis Appoints James P. Abraham as Senior Vice President Sales" issued on 16 Apr 2007 12:00 GMT, by Isotis Inc nasdaq:ISOT over PR Newswire, we are advised by a representative of the company that the release is the same for several wire tasks, so the destinations will be added to this task transmitted by PR Newswire. Complete, corrected release follows: ...

  • 14.02.2007 – 15:14

    IsoTis Reports Preliminary 2006 and Q4 Revenue

    Irvine, California (ots/PRNewswire) - - Update on Recent Events IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today reported preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2006. Revenue was approximately US$10 million (unaudited) for the fourth quarter of 2006, representing a 16% increase over revenue of the fourth quarter of 2005. For the full year 2006, ...

  • 30.01.2007 – 00:13

    IsoTis, Inc. Files Registration Statement for Public Offering

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (Nasdaq: ISOT), the orthobiologics company, announced today that it has filed a Form S-1 registration statement with the Securities and Exchange Commission for a proposed public offering of its common stock. The lead underwriter for the offering is Thomas Weisel Partners LLC. William Blair & Company is acting as co-manager. The offering will be made only by means ...

  • 11.08.2004 – 08:08

    /OFF HOLD OFF HOLD OFF HOLD -- IsoTis OrthoBiologics/

    Lausanne, Switzerland and Irvine, California (ots/PRNewswire) - Please add the following ticker symbols to the first paragraph of the release. (SWX/Euronext: ISO; TSX: ISO; Reuters: ISON.S; Reuters: ISO.TO; ASX: ISON.AS) IsoTis OrthoBiologics (SWX/Euronext: ISO; TSX: ISO; Reuters: ISON.S; Reuters: ISO.TO; ASX: ISON.AS) today reported a 16% increase in orthobiologics sales of US$12.9 million for the first six ...

  • 11.08.2004 – 07:40

    /ON HOLD ON HOLD ON HOLD -- IsoTis OrthoBiologics/

    /ON HOLD ON HOLD ON HOLD -- IsoTis OrthoBiologics, EDB1011437 Please place the following release: "IsoTis Announces 16% H1 Orthobiologics Sales Growth, and Provides Further 04 & 05 Guidance" ON HOLD. ots Originaltext: IsoTis OrthoBiologics Im Internet recherchierbar: http://www.newsaktuell.ch Contact: Hans Herklots, +41-21-620-6011, Fax: +41-21-620-6060, hans.herklots@isotis.com, or Louis G. Plourde, ...

  • 11.08.2004 – 07:37

    IsoTis Announces 16% H1 Orthobiologics Sales Growth, and Provides Further 04 & 05 Guidance

    Lausanne, Switzerland and Irvine, California (ots/PRNewswire) - IsoTis OrthoBiologics (SWX/Euronext: ISON; TSX: ISO) today reported a 16% increase in orthobiologics sales of US$12.9 million for the first six months of fiscal 2004, compared to pro-forma orthobiologics sales of US$11.1 million for the first six months of 2003. Sales for the second quarter 2004 were ...